Flutamide interactions
Full monograph for FlutamideCheck it against another medicine
Medicines
269 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Synergy | Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 16 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartrate | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Benzocaine + Butamben + Tetracaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 12 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Bupivacaine Hydrochloride + Dextrose | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Cabozantinib | Major | Synergy | Cabozantinib can cause prolongation of the QT interval. | 7 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Synergy · Unknown | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 5 sources — open the full entry |
| Ceritinib | Major | Synergy | Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clozapine | Major | Synergy | Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation… | 13 sources — open the full entry |
| Crizotinib | Major | Synergy | Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Major | Synergy · Unknown | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 5 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Hydrocortisone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Ivabradine | Major | Synergy | Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong… | 10 sources — open the full entry |
| Ivosidenib | Major | Synergy | Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive… | 6 sources — open the full entry |
| Lefamulin Acetate | Major | Synergy | Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Lidocaine + Adrenaline | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Epinephrine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Lidocaine + Prilocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…3 documented mechanisms | 18 sources — open the full entry |
| Lidocaine HydrochlorideInjectionSpray | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Loteprednol Etabonate + Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Mifepristone | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Moxifloxacin HydrochlorideInjectionOphthalmicTablet | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Xanthan Gum | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Nilotinib | Major | Synergy | Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Ofloxacin + Clotrimazole + Beclomethasone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine…2 documented mechanisms | 13 sources — open the full entry |
| Osimertinib | Major | Synergy | Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 5 sources — open the full entry |
| Ribociclib | Major | Synergy | Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 16 sources — open the full entry |
| Selpercatinib | Major | Synergy | Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Sotalol Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Sparfloxacin | Major | Synergy | Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT… | 21 sources — open the full entry |
| Tolperisone + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Tropicamide + Phenylephrine + Lidocaine | Major | Synergy | Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine… | 5 sources — open the full entry |
| Ziprasidone | Major | Synergy | Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
Conditions
Conditions in which Flutamide needs care, as documented in this source.
Liver Diseases
MajorThere have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide. Signs of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment. Serum transaminase levels should be measured prior to starting treatment with flutamide. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, hyperbilirubinuria, jaundice or right upper quadrant tenderness. If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests. Flutamide should be administered with extreme caution in patients with or predisposed to compromised hepatic function, and it is contraindicated in patients with severe hepatic impairment.
16 sources
- Gomez J-L, Dupont A, Cusan L, et al. "Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients." Am J Med 92 (1992): 465-70
- Hart W, Stricker BH "Flutamide and hepatitis ." Ann Intern Med 110 (1989): 943-4
- Wysowski DK, Freiman JP, Tourtelot JB, Horton ML "Fatal and nonfatal hepatotoxicity associated with flutamide." Ann Intern Med 118 (1993): 860-4
- Dankoff JS "Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer." J Urol 148 (1992): 1914
- Moller S, Iversen P, Franzmann MB, Mller S "Flutamide-induced liver failure." J Hepatol 10 (1990): 346-9
- "Product Information. Eulexin (flutamide)." Schering Corporation (2002):
- Wallace C, Lalor EA, Chik CL "Hepatotoxicity complicating flutamide treatment of hirsutism." Ann Intern Med 119 (1993): 1150
- Wysowski DK, Fourcroy JL "Hepatotoxicity complicating flutamide treatment of hirsutism - reply." Ann Intern Med 119 (1993): 1150
Show all 16 sourcesShow fewer sources
- Labrie F "Acute cholestatic hepatitis secondary to flutamide therapy - reply." Am J Med 96 (1994): 392-3
- Dourakis SP, Alexopoulou AA, Hadziyannis SJ "Fulminant hepatitis after flutamide treatment." J Hepatol 20 (1994): 350-3
- Moghetti P, Castello R, Negri C, Tosi F, Magnani CM, Fontanarosa MC, Armanini D, Muggeo M "Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior." Fertil Steril 64 (1995): 511-7
- Wysowski DK, Fourcroy JL "Flutamide hepatotoxicity." J Urol 155 (1996): 209-12
- Crownover RL, Holland J, Chen A, Krieg R, Young BK, Roach M, Fu KK "Flutamide-induced liver toxicity including fatal hepatic necrosis." Int J Radiat Oncol Biol Phys 34 (1996): 911-5
- Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, Gilbert RM "Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer." Radiology 199 (1996): 451-5
- Wysowski DK, Fourcroy JL "Flutamide hepatotoxicity." J Urol 155 (1996): 209-12
- Cicognani C, Malavolti M, Morsellilabate AM, Sama C, Barbara L "Flutamide-induced toxic hepatitis: potential utility of ursodeoxycholic acid administration in toxic hepatitis." Dig Dis Sci 41 (1996): 2219-21
Hemolysis
ModerateToxicity consistent with aniline exposure such as methemoglobinemia, hemolytic anemia, and cholestatic jaundice has been reported during flutamide therapy. Therapy with flutamide should be administered cautiously in patients with glucose-6-phosphate deficiency, hemoglobin M disease, and patients who smoke. Clinical monitoring of methemoglobin levels in susceptible individuals is recommended,
3 sources
- Schott AM, Vial T, Gozzo I, Chareyre S, Delmas PD "Flutamide-induced methemoglobinemia." DICP 25 (1991): 600-1
- "Product Information. Eulexin (flutamide)." Schering Corporation (2002):
- Kouides PA, Abboud CN, Fairbanks VF "Flutamide-induced cyanosis refractory to methylene blue therapy." Br J Haematol 94 (1996): 73-5
Therapeutic duplication
Drug classes that overlap with Flutamide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antineoplastic hormones
The recommended maximum number of medicines in the 'antineoplastic hormones' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antineoplastic hormones' category.
Example product in the source data (US market): Letrozole/ribociclib